메뉴 건너뛰기




Volumn 13, Issue 12, 2014, Pages 2769-2783

Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma

Author keywords

[No Author keywords available]

Indexed keywords

3 (2,6 DICHLORO 3,5 DIMETHOXYPHENYL) 1 [6 [[4 (4 ETHYL 1 PIPERAZINYL)PHENYL]AMINO] 4 PYRIMIDINYL] 1 METHYLUREA; 4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; ALPHA2B INTERFERON; B RAF KINASE; B RAF KINASE INHIBITOR; BINIMETINIB; BUPARLISIB; CAPMATINIB; CHIR 265; COBIMETINIB; CYCLOPHOSPHAMIDE; DABRAFENIB; DACARBAZINE; ENCORAFENIB; FAMOTIDINE; FLUDARABINE; IPILIMUMAB; PLACEBO; RECOMBINANT INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 2; RIBOCICLIB; SORAFENIB; TRAMETINIB; VEMURAFENIB; XL 281; PROTEIN KINASE INHIBITOR;

EID: 84917673811     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0290     Document Type: Review
Times cited : (74)

References (75)
  • 1
    • 57449086541 scopus 로고    scopus 로고
    • Melanoma epidemiology and trends
    • Garbe C, Leiter U. Melanoma epidemiology and trends. Clin Dermatol 2009;27:3-9.
    • (2009) Clin Dermatol , vol.27 , pp. 3-9
    • Garbe, C.1    Leiter, U.2
  • 3
    • 70350580555 scopus 로고    scopus 로고
    • Adjuvant interferon alfa for melanoma: New evidencebased treatment recommendations?
    • Hauschild A. Adjuvant interferon alfa for melanoma: new evidencebased treatment recommendations? Curr Oncol 2009;16:3-6.
    • (2009) Curr Oncol , vol.16 , pp. 3-6
    • Hauschild, A.1
  • 4
    • 84883237132 scopus 로고    scopus 로고
    • Dabrafenib: First global approval
    • Ballantyne AD, Garnock-Jones KP. Dabrafenib: first global approval. Drugs 2013;73:1367-76.
    • (2013) Drugs , vol.73 , pp. 1367-1376
    • Ballantyne, A.D.1    Garnock-Jones, K.P.2
  • 6
    • 84880780573 scopus 로고    scopus 로고
    • Trametinib: First global approval
    • Wright CJ, McCormack PL. Trametinib: first global approval. Drugs 2013;73:1245-54.
    • (2013) Drugs , vol.73 , pp. 1245-1254
    • Wright, C.J.1    McCormack, P.L.2
  • 7
    • 84859401047 scopus 로고    scopus 로고
    • Advances in the treatment of metastatic melanoma: New immunomodulatory agents
    • Sznol M. Advances in the treatment of metastatic melanoma: new immunomodulatory agents. Semin Oncol 2012;39:192-203.
    • (2012) Semin Oncol , vol.39 , pp. 192-203
    • Sznol, M.1
  • 8
    • 84884270901 scopus 로고    scopus 로고
    • Immune alterations in malignant melanoma and current immunotherapy concepts
    • Shimanovsky A, Jethava A, Dasanu CA. Immune alterations in malignant melanoma and current immunotherapy concepts. Expert Opin Biol Ther 2013;13:1413-27.
    • (2013) Expert Opin Biol Ther , vol.13 , pp. 1413-1427
    • Shimanovsky, A.1    Jethava, A.2    Dasanu, C.A.3
  • 9
    • 84858276057 scopus 로고    scopus 로고
    • Regulatory T cells stimulate B7-H1 expression in myeloid-derived suppressor cells in ret melanomas
    • Fujimura T, Ring S, Umansky V, Mahnke K, Enk AH. Regulatory T cells stimulate B7-H1 expression in myeloid-derived suppressor cells in ret melanomas. J Invest Dermatol 2012;132:1239-46.
    • (2012) J Invest Dermatol , vol.132 , pp. 1239-1246
    • Fujimura, T.1    Ring, S.2    Umansky, V.3    Mahnke, K.4    Enk, A.H.5
  • 10
    • 84865504759 scopus 로고    scopus 로고
    • Tumour-derived IL-10 within tumour microenvironment represses the antitumour immunity of Socs1-silenced and sustained antigen expressing DCs
    • Song S, Wang Y, Wang J, Lian W, Liu S, Zhang Z, et al. Tumour-derived IL-10 within tumour microenvironment represses the antitumour immunity of Socs1-silenced and sustained antigen expressing DCs. Eur J Cancer 2012;48:2252-9.
    • (2012) Eur J Cancer , vol.48 , pp. 2252-2259
    • Song, S.1    Wang, Y.2    Wang, J.3    Lian, W.4    Liu, S.5    Zhang, Z.6
  • 11
    • 79955778025 scopus 로고    scopus 로고
    • Monitoring the systemic human memory B-cell compartment of melanoma patients for anti-tumor IgG antibodies
    • Gilbert AE, Karagiannis P, Dodev T, Koers A, Lacy K, Josephs DH, et al. Monitoring the systemic human memory B-cell compartment of melanoma patients for anti-tumor IgG antibodies. PLoS ONE 2011;6:e19330.
    • (2011) PLoS ONE , vol.6 , pp. e19330
    • Gilbert, A.E.1    Karagiannis, P.2    Dodev, T.3    Koers, A.4    Lacy, K.5    Josephs, D.H.6
  • 13
    • 84862076074 scopus 로고    scopus 로고
    • Tumor-expressed inducible nitric oxide synthase controls induction of functional myeloid-derived suppressor cells through modulation of vascular endothelial growth factor release
    • Jayaraman P, Parikh F, Lopez-Rivera E, Hailemichael Y, Clark A, Ma G, et al. Tumor-expressed inducible nitric oxide synthase controls induction of functional myeloid-derived suppressor cells through modulation of vascular endothelial growth factor release. J Immunol 2012;188:5365-76.
    • (2012) J Immunol , vol.188 , pp. 5365-5376
    • Jayaraman, P.1    Parikh, F.2    Lopez-Rivera, E.3    Hailemichael, Y.4    Clark, A.5    Ma, G.6
  • 14
    • 84862663385 scopus 로고    scopus 로고
    • Melanoma-derived conditioned media efficiently induce the differentiation of monocytes to macrophages that display a highly invasive gene signature
    • Wang T, Ge Y, Xiao M, Lopez-Coral A, Azuma R, Somasundaram R, et al. Melanoma-derived conditioned media efficiently induce the differentiation of monocytes to macrophages that display a highly invasive gene signature. Pigment Cell Melanoma Res 2012;25:493-505.
    • (2012) Pigment Cell Melanoma Res , vol.25 , pp. 493-505
    • Wang, T.1    Ge, Y.2    Xiao, M.3    Lopez-Coral, A.4    Azuma, R.5    Somasundaram, R.6
  • 15
    • 84855338629 scopus 로고    scopus 로고
    • Regulatory T cells in melanoma: The final hurdle towards effective immunotherapy?
    • Jacobs JF, Nierkens S, Figdor CG, de Vries IJ, Adema GJ. Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy? Lancet Oncol 2012;13:e32-42.
    • (2012) Lancet Oncol , vol.13 , pp. e32-e42
    • Jacobs, J.F.1    Nierkens, S.2    Figdor, C.G.3    De Vries, I.J.4    Adema, G.J.5
  • 16
    • 84871127292 scopus 로고    scopus 로고
    • Tumor-in filtrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth
    • Schlecker E, Stojanovic A, Eisen C, Quack C, Falk CS, Umansky V, et al. Tumor-in filtrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth. J Immunol 2012;189:5602-11.
    • (2012) J Immunol , vol.189 , pp. 5602-5611
    • Schlecker, E.1    Stojanovic, A.2    Eisen, C.3    Quack, C.4    Falk, C.S.5    Umansky, V.6
  • 17
    • 84865316603 scopus 로고    scopus 로고
    • Immunomodulating antibodies in the treatment of metastatic melanoma: The experience with anti-CTLA-4, anti-CD137, and anti-PD1
    • Simeone E, Ascierto PA. Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1. J Immunotoxicol 2012;9:241-7.
    • (2012) J Immunotoxicol , vol.9 , pp. 241-247
    • Simeone, E.1    Ascierto, P.A.2
  • 19
    • 84880310548 scopus 로고    scopus 로고
    • Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials
    • Wolchok JD, Weber JS, Maio M, Neyns B, Harmankaya K, Chin K, et al. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Ann Oncol 2013;24:2174-80.
    • (2013) Ann Oncol , vol.24 , pp. 2174-2180
    • Wolchok, J.D.1    Weber, J.S.2    Maio, M.3    Neyns, B.4    Harmankaya, K.5    Chin, K.6
  • 21
    • 79952112019 scopus 로고    scopus 로고
    • The MAP kinase signaling cascades: A system of hundreds of components regulates a diverse array of physiological functions
    • Keshet Y, Seger R. The MAP kinase signaling cascades: a system of hundreds of components regulates a diverse array of physiological functions. Methods Mol Biol 2010;661:3-38.
    • (2010) Methods Mol Biol , vol.661 , pp. 3-38
    • Keshet, Y.1    Seger, R.2
  • 22
    • 34248591612 scopus 로고    scopus 로고
    • Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
    • Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007;26:3291-310.
    • (2007) Oncogene , vol.26 , pp. 3291-3310
    • Roberts, P.J.1    Der, C.J.2
  • 24
    • 5444227865 scopus 로고    scopus 로고
    • Guilty as charged: B-RAF is a human oncogene
    • Garnett MJ, Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell 2004;6:313-9.
    • (2004) Cancer Cell , vol.6 , pp. 313-319
    • Garnett, M.J.1    Marais, R.2
  • 25
    • 12144289677 scopus 로고    scopus 로고
    • Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF
    • Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116:855-67.
    • (2004) Cell , vol.116 , pp. 855-867
    • Wan, P.T.1    Garnett, M.J.2    Roe, S.M.3    Lee, S.4    Niculescu-Duvaz, D.5    Good, V.M.6
  • 26
    • 67049154293 scopus 로고    scopus 로고
    • The crystal structure of BRAFin complex with an organoruthenium inhibitor reveals a mechanism for inhibition of an active form of BRAF kinase
    • Xie P, Streu C, Qin J, Bregman H, Pagano N, Meggers E, et al. The crystal structure of BRAFin complex with an organoruthenium inhibitor reveals a mechanism for inhibition of an active form of BRAF kinase. Biochemistry 2009;48:5187-98.
    • (2009) Biochemistry , vol.48 , pp. 5187-5198
    • Xie, P.1    Streu, C.2    Qin, J.3    Bregman, H.4    Pagano, N.5    Meggers, E.6
  • 27
    • 79960848073 scopus 로고    scopus 로고
    • Sorafenib and dacarbazine as fi rst-line therapy for advanced melanoma: Phase I and open-label phase II studies
    • Eisen T, Marais R, Affolter A, Lorigan P, Robert C, Corrie P, et al. Sorafenib and dacarbazine as fi rst-line therapy for advanced melanoma: phase I and open-label phase II studies. Br J Cancer 2011;105:353-9.
    • (2011) Br J Cancer , vol.105 , pp. 353-359
    • Eisen, T.1    Marais, R.2    Affolter, A.3    Lorigan, P.4    Robert, C.5    Corrie, P.6
  • 28
    • 67649909568 scopus 로고    scopus 로고
    • Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma
    • Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, Hersey P, et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009;27:2823-30.
    • (2009) J Clin Oncol , vol.27 , pp. 2823-2830
    • Hauschild, A.1    Agarwala, S.S.2    Trefzer, U.3    Hogg, D.4    Robert, C.5    Hersey, P.6
  • 29
    • 84865068182 scopus 로고    scopus 로고
    • Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma
    • abstr 8502
    • Chapman PB, Hauschild A, Robert C, Larkin JMG, Haanen JBAG, Ribas A, et al. Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma. J Clin Oncol 2012;30 (suppl; abstr 8502).
    • (2012) J Clin Oncol , vol.30
    • Chapman, P.B.1    Hauschild, A.2    Robert, C.3    Larkin, J.M.G.4    Haanen, J.B.A.G.5    Ribas, A.6
  • 30
    • 84876130561 scopus 로고    scopus 로고
    • The European Medicines Agency review of vemurafenib (Zelboraf(R)) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: Summary of the scienti fi c assessment of the Committee for Medicinal Products for Human Use
    • da Rocha Dias S, Salmonson T, van Zwieten-Boot B, Jonsson B, Marchetti S, Schellens JH, et al. The European Medicines Agency review of vemurafenib (Zelboraf(R)) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: summary of the scienti fi c assessment of the Committee for Medicinal Products for Human Use. Eur J Cancer 2013;49:1654-61.
    • (2013) Eur J Cancer , vol.49 , pp. 1654-1661
    • Da Rocha Dias, S.1    Salmonson, T.2    Van Zwieten-Boot, B.3    Jonsson, B.4    Marchetti, S.5    Schellens, J.H.6
  • 31
    • 84896714827 scopus 로고    scopus 로고
    • Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF (V600K) mutation-positive melanoma (BRIM-3): Extended follow-up of a phase 3, randomised, open-label study
    • McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF (V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014;15:323-32.
    • (2014) Lancet Oncol , vol.15 , pp. 323-332
    • McArthur, G.A.1    Chapman, P.B.2    Robert, C.3    Larkin, J.4    Haanen, J.B.5    Dummer, R.6
  • 32
    • 84873360893 scopus 로고    scopus 로고
    • Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents
    • Mao M, Tian F, Mariadason JM, Tsao CC, Lemos RJr, Dayyani F, et al. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res 2013;19:657-67.
    • (2013) Clin Cancer Res , vol.19 , pp. 657-667
    • Mao, M.1    Tian, F.2    Mariadason, J.M.3    Tsao, C.C.4    Lemos, R.5    Dayyani, F.6
  • 36
    • 84868203567 scopus 로고    scopus 로고
    • Dividing and conquering: Controlling advanced melanoma by targeting oncogene-defined subsets
    • Flaherty KT. Dividing and conquering: controlling advanced melanoma by targeting oncogene-defined subsets. Clin Exp Metastasis 2012;29:841-6.
    • (2012) Clin Exp Metastasis , vol.29 , pp. 841-846
    • Flaherty, K.T.1
  • 37
    • 77949354563 scopus 로고    scopus 로고
    • PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells
    • Halaban R, Zhang W, Bacchiocchi A, Cheng E, Parisi F, Ariyan S, et al. PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res 2010;23:190-200.
    • (2010) Pigment Cell Melanoma Res , vol.23 , pp. 190-200
    • Halaban, R.1    Zhang, W.2    Bacchiocchi, A.3    Cheng, E.4    Parisi, F.5    Ariyan, S.6
  • 38
    • 84864285704 scopus 로고    scopus 로고
    • Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial
    • Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012;380:358-65.
    • (2012) Lancet , vol.380 , pp. 358-365
    • Hauschild, A.1    Grob, J.J.2    Demidov, L.V.3    Jouary, T.4    Gutzmer, R.5    Millward, M.6
  • 39
    • 79952261716 scopus 로고    scopus 로고
    • GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition
    • Gilmartin AG, Bleam MR, Groy A, Moss KG, Minthorn EA, Kulkarni SG, et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res 2011;17:989-1000.
    • (2011) Clin Cancer Res , vol.17 , pp. 989-1000
    • Gilmartin, A.G.1    Bleam, M.R.2    Groy, A.3    Moss, K.G.4    Minthorn, E.A.5    Kulkarni, S.G.6
  • 41
    • 1642363984 scopus 로고    scopus 로고
    • CD4(+) T-cell recognition of mutated B-RAF in melanoma patients harboring the V599E mutation
    • Sharkey MS, Lizee G, Gonzales MI, Patel S, Topalian SL. CD4(+) T-cell recognition of mutated B-RAF in melanoma patients harboring the V599E mutation. Cancer Res 2004;64:1595-9.
    • (2004) Cancer Res , vol.64 , pp. 1595-1599
    • Sharkey, M.S.1    Lizee, G.2    Gonzales, M.I.3    Patel, S.4    Topalian, S.L.5
  • 43
    • 33645531525 scopus 로고    scopus 로고
    • Human leukocyte antigen-A2-restricted CTL responses to mutated BRAF peptides in melanoma patients
    • Somasundaram R, Swoboda R, Caputo L, Otvos L, Weber B, Volpe P, et al. Human leukocyte antigen-A2-restricted CTL responses to mutated BRAF peptides in melanoma patients. Cancer Res 2006;66: 3287-93.
    • (2006) Cancer Res , vol.66 , pp. 3287-3293
    • Somasundaram, R.1    Swoboda, R.2    Caputo, L.3    Otvos, L.4    Weber, B.5    Volpe, P.6
  • 44
    • 84883008576 scopus 로고    scopus 로고
    • BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer
    • Donia M, Fagone P, Nicoletti F, Andersen RS, Hogdall E, Straten PT, et al. BRAF inhibition improves tumor recognition by the immune system: potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer. Oncoimmunology 2012;1:1476-83.
    • (2012) Oncoimmunology , vol.1 , pp. 1476-1483
    • Donia, M.1    Fagone, P.2    Nicoletti, F.3    Andersen, R.S.4    Hogdall, E.5    Straten, P.T.6
  • 45
    • 33745859743 scopus 로고    scopus 로고
    • The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells
    • Sumimoto H, Imabayashi F, Iwata T, Kawakami Y. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med 2006;203:1651-6.
    • (2006) J Exp Med , vol.203 , pp. 1651-1656
    • Sumimoto, H.1    Imabayashi, F.2    Iwata, T.3    Kawakami, Y.4
  • 46
    • 84866918738 scopus 로고    scopus 로고
    • Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma
    • Khalili JS, Liu S, Rodriguez-Cruz TG, Whittington M, Wardell S, Liu C, et al. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res 2012;18:5329-40.
    • (2012) Clin Cancer Res , vol.18 , pp. 5329-5340
    • Khalili, J.S.1    Liu, S.2    Rodriguez-Cruz, T.G.3    Whittington, M.4    Wardell, S.5    Liu, C.6
  • 47
    • 84885816614 scopus 로고    scopus 로고
    • Vemurafenib enhances MHC induction in BRAF homozygous melanoma cells
    • Sapkota B, Hill CE, Pollack BP. Vemurafenib enhances MHC induction in BRAF homozygous melanoma cells. Oncoimmunology 2013;2:e22890.
    • (2013) Oncoimmunology , vol.2 , pp. e22890
    • Sapkota, B.1    Hill, C.E.2    Pollack, B.P.3
  • 48
    • 78650391890 scopus 로고    scopus 로고
    • The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations
    • Comin-Anduix B, Chodon T, Sazegar H, Matsunaga D, Mock S, Jalil J, et al. The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations. Clin Cancer Res 2010;16:6040-8.
    • (2010) Clin Cancer Res , vol.16 , pp. 6040-6048
    • Comin-Anduix, B.1    Chodon, T.2    Sazegar, H.3    Matsunaga, D.4    Mock, S.5    Jalil, J.6
  • 49
    • 84864257724 scopus 로고    scopus 로고
    • Immunologic effects of an orally available BRAFV600E inhibitor in BRAF wild-type murine models
    • Vosganian GS, Bos R, Sherman LA. Immunologic effects of an orally available BRAFV600E inhibitor in BRAF wild-type murine models. J Immunother 2012;35:473-7.
    • (2012) J Immunother , vol.35 , pp. 473-477
    • Vosganian, G.S.1    Bos, R.2    Sherman, L.A.3
  • 50
    • 77954373338 scopus 로고    scopus 로고
    • Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function
    • Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 2010;70:5213-9.
    • (2010) Cancer Res , vol.70 , pp. 5213-5219
    • Boni, A.1    Cogdill, A.P.2    Dang, P.3    Udayakumar, D.4    Njauw, C.N.5    Sloss, C.M.6
  • 51
    • 84859807701 scopus 로고    scopus 로고
    • BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency
    • Hong DS, Vence L, Falchook G, Radvanyi LG, Liu C, Goodman V, et al. BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. Clin Cancer Res 2012;18:2326-35.
    • (2012) Clin Cancer Res , vol.18 , pp. 2326-2335
    • Hong, D.S.1    Vence, L.2    Falchook, G.3    Radvanyi, L.G.4    Liu, C.5    Goodman, V.6
  • 52
    • 84872688870 scopus 로고    scopus 로고
    • Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma
    • Hooijkaas A, Gadiot J, Morrow M, Stewart R, Schumacher T, Blank CU. Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma. Oncoimmunology 2012;1:609-17.
    • (2012) Oncoimmunology , vol.1 , pp. 609-617
    • Hooijkaas, A.1    Gadiot, J.2    Morrow, M.3    Stewart, R.4    Schumacher, T.5    Blank, C.U.6
  • 53
    • 84884271914 scopus 로고    scopus 로고
    • Fc-dependent depletion of tumor-in filtrating regulatory T cells co-defines the ef ficacy of anti-CTLA-4 therapy against melanoma
    • Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, et al. Fc-dependent depletion of tumor-in filtrating regulatory T cells co-defines the ef ficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 2013;210:1695-710.
    • (2013) J Exp Med , vol.210 , pp. 1695-1710
    • Simpson, T.R.1    Li, F.2    Montalvo-Ortiz, W.3    Sepulveda, M.A.4    Bergerhoff, K.5    Arce, F.6
  • 54
    • 68149155982 scopus 로고    scopus 로고
    • Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies
    • Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 2009;206:1717-25.
    • (2009) J Exp Med , vol.206 , pp. 1717-1725
    • Peggs, K.S.1    Quezada, S.A.2    Chambers, C.A.3    Korman, A.J.4    Allison, J.P.5
  • 56
    • 84877817680 scopus 로고    scopus 로고
    • Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties
    • Ott PA, Henry T, Baranda SJ, Frleta D, Manches O, Bogunovic D, et al. Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties. Cancer Immunol Immunother 2013;62:811-22.
    • (2013) Cancer Immunol Immunother , vol.62 , pp. 811-822
    • Ott, P.A.1    Henry, T.2    Baranda, S.J.3    Frleta, D.4    Manches, O.5    Bogunovic, D.6
  • 57
    • 84880294344 scopus 로고    scopus 로고
    • Vemurafenib reverses immunosuppression by myeloid derived suppressor cells
    • Schilling B, Sucker A, Griewank K, Zhao F, Weide B, Gorgens A, et al. Vemurafenib reverses immunosuppression by myeloid derived suppressor cells. Int J Cancer 2013;133:1653-63.
    • (2013) Int J Cancer , vol.133 , pp. 1653-1663
    • Schilling, B.1    Sucker, A.2    Griewank, K.3    Zhao, F.4    Weide, B.5    Gorgens, A.6
  • 58
    • 84903464388 scopus 로고    scopus 로고
    • Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNgamma
    • Ho PC, Meeth KM, Tsui YC, Srivastava B, Bosenberg MW, Kaech SM. Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNgamma. Cancer Res 2014;74:3205-17.
    • (2014) Cancer Res , vol.74 , pp. 3205-3217
    • Ho, P.C.1    Meeth, K.M.2    Tsui, Y.C.3    Srivastava, B.4    Bosenberg, M.W.5    Kaech, S.M.6
  • 59
    • 84874595712 scopus 로고    scopus 로고
    • Host immunity contributes to the anti-melanoma activity of BRAF inhibitors
    • Knight DA, Ngiow SF, Li M, Parmenter T, Mok S, Cass A, et al. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest 2013;123:1371-81.
    • (2013) J Clin Invest , vol.123 , pp. 1371-1381
    • Knight, D.A.1    Ngiow, S.F.2    Li, M.3    Parmenter, T.4    Mok, S.5    Cass, A.6
  • 60
    • 84873336707 scopus 로고    scopus 로고
    • The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition
    • Jiang X, Zhou J, Giobbie-Hurder A, Wargo J, Hodi FS. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin Cancer Res 2013;19:598-609.
    • (2013) Clin Cancer Res , vol.19 , pp. 598-609
    • Jiang, X.1    Zhou, J.2    Giobbie-Hurder, A.3    Wargo, J.4    Hodi, F.S.5
  • 62
    • 84874872137 scopus 로고    scopus 로고
    • BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma
    • Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 2013; 19:1225-31.
    • (2013) Clin Cancer Res , vol.19 , pp. 1225-1231
    • Frederick, D.T.1    Piris, A.2    Cogdill, A.P.3    Cooper, Z.A.4    Lezcano, C.5    Ferrone, C.R.6
  • 63
    • 84865112760 scopus 로고    scopus 로고
    • BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy
    • Koya RC, Mok S, Otte N, Blacketor KJ, Comin-Anduix B, Tumeh PC, et al. BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res 2012;72:3928-37.
    • (2012) Cancer Res , vol.72 , pp. 3928-3937
    • Koya, R.C.1    Mok, S.2    Otte, N.3    Blacketor, K.J.4    Comin-Anduix, B.5    Tumeh, P.C.6
  • 64
    • 84872514398 scopus 로고    scopus 로고
    • BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice
    • Liu C, Peng W, Xu C, Lou Y, Zhang M, Wargo JA, et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res 2013;19:393-403.
    • (2013) Clin Cancer Res , vol.19 , pp. 393-403
    • Liu, C.1    Peng, W.2    Xu, C.3    Lou, Y.4    Zhang, M.5    Wargo, J.A.6
  • 65
    • 84878952482 scopus 로고    scopus 로고
    • Combination molecularly targeted drug therapy in metastatic melanoma: Progress to date
    • Lemech C, Infante J, Arkenau HT. Combination molecularly targeted drug therapy in metastatic melanoma: progress to date. Drugs 2013;73:767-77.
    • (2013) Drugs , vol.73 , pp. 767-777
    • Lemech, C.1    Infante, J.2    Arkenau, H.T.3
  • 66
    • 84875785905 scopus 로고    scopus 로고
    • Hepatotoxicity with combination of vemurafenib and ipilimumab
    • Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 2013;368: 1365-6.
    • (2013) N Engl J Med , vol.368 , pp. 1365-1366
    • Ribas, A.1    Hodi, F.S.2    Callahan, M.3    Konto, C.4    Wolchok, J.5
  • 67
    • 84886944616 scopus 로고    scopus 로고
    • Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma
    • Cooper ZA, Frederick DT, Ahmed Z, Wargo JA. Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma. Oncoimmunology 2013;2:e24320.
    • (2013) Oncoimmunology , vol.2 , pp. e24320
    • Cooper, Z.A.1    Frederick, D.T.2    Ahmed, Z.3    Wargo, J.A.4
  • 68
    • 84886119112 scopus 로고    scopus 로고
    • Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme
    • Altomonte M, Di Giacomo A, Queirolo P, Ascierto P, Spagnolo F, Bajetta E, et al. Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme. J Exp Clin Cancer Res 2013;32:82.
    • (2013) J Exp Clin Cancer Res , vol.32 , pp. 82
    • Altomonte, M.1    Di Giacomo, A.2    Queirolo, P.3    Ascierto, P.4    Spagnolo, F.5    Bajetta, E.6
  • 69
    • 84901340078 scopus 로고    scopus 로고
    • Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors
    • Ackerman A, Klein O, McDermott DF, Wang W, Ibrahim N, Lawrence DP, et al. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer 2014;120:1695-701.
    • (2014) Cancer , vol.120 , pp. 1695-1701
    • Ackerman, A.1    Klein, O.2    McDermott, D.F.3    Wang, W.4    Ibrahim, N.5    Lawrence, D.P.6
  • 70
    • 84873819555 scopus 로고    scopus 로고
    • Which drug, and when, for patients with BRAFmutant melanoma?
    • Jang S, Atkins MB. Which drug, and when, for patients with BRAFmutant melanoma? Lancet Oncol 2013;14:e60-9.
    • (2013) Lancet Oncol , vol.14 , pp. e60-e69
    • Jang, S.1    Atkins, M.B.2
  • 71
    • 84872595484 scopus 로고    scopus 로고
    • BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene pro file predict poor outcome in patients with stage III melanoma
    • Mann GJ, Pupo GM, Campain AE, Carter CD, Schramm SJ, Pianova S, et al. BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene pro file predict poor outcome in patients with stage III melanoma. J Invest Dermatol 2013;133:509-17.
    • (2013) J Invest Dermatol , vol.133 , pp. 509-517
    • Mann, G.J.1    Pupo, G.M.2    Campain, A.E.3    Carter, C.D.4    Schramm, S.J.5    Pianova, S.6
  • 73
    • 84891898344 scopus 로고    scopus 로고
    • Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy
    • Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov 2014;4:80-93.
    • (2014) Cancer Discov , vol.4 , pp. 80-93
    • Shi, H.1    Hugo, W.2    Kong, X.3    Hong, A.4    Koya, R.C.5    Moriceau, G.6
  • 74
    • 84891893623 scopus 로고    scopus 로고
    • A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition
    • Shi H, Hong A, Kong X, Koya RC, Song C, Moriceau G, et al. A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov 2014;4:69-79.
    • (2014) Cancer Discov , vol.4 , pp. 69-79
    • Shi, H.1    Hong, A.2    Kong, X.3    Koya, R.C.4    Song, C.5    Moriceau, G.6
  • 75
    • 77954234849 scopus 로고    scopus 로고
    • Gene expression profi ling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome
    • Jonsson G, Busch C, Knappskog S, Geisler J, Miletic H, Ringner M, et al. Gene expression profi ling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome. Clin Cancer Res 2010;16:3356-67.
    • (2010) Clin Cancer Res , vol.16 , pp. 3356-3367
    • Jonsson, G.1    Busch, C.2    Knappskog, S.3    Geisler, J.4    Miletic, H.5    Ringner, M.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.